A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Public ClinicalTrials.gov record NCT07227402. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Researchers are looking for more ways to treat advanced renal cell carcinoma (RCC) that is recurrent. Researchers want to learn if recurrent advanced renal cell carcinoma (RCC) responds (gets smaller or goes away) after treatment with belzutifan (MK-6482) and zanzalintinib compared to cabozantinib. The goal of this study is to learn if: People who take belzutifan and zanzalintinib live longer overall and without the cancer getting worse than people who take cabozantinib.
Study identification
- NCT ID
- NCT07227402
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 904 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 25, 2025
- Primary completion
- Feb 26, 2032
- Completion
- Feb 26, 2032
- Last update posted
- Aug 2, 2026
2025 – 2032
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alaska Oncology and Hematology ( Site 0133) | Anchorage | Alaska | 99508 | Recruiting |
| Providence Medical Foundation ( Site 0141) | Fullerton | California | 92835 | Recruiting |
| USC Norris Comprehensive Cancer Center ( Site 0126) | Los Angeles | California | 90033 | Recruiting |
| Cedars-Sinai Medical Center ( Site 0112) | Los Angeles | California | 90048 | Recruiting |
| New England Cancer Specialists ( Site 0132) | Westbrook | Maine | 04092 | Recruiting |
| Greater Baltimore Medical Center ( Site 0145) | Baltimore | Maryland | 21204 | Recruiting |
| Metro-Minnesota Community Clinical Oncology ( Site 0144) | Saint Louis Park | Minnesota | 55426 | Recruiting |
| Oncology Hematology West P.C. dba Nebraska Cancer Specialists ( Site 0131) | Omaha | Nebraska | 68130-2042 | Recruiting |
| Carolina Oncology Specialists, PA ( Site 9002) | Charlotte | North Carolina | 28207 | Recruiting |
| Thompson Cancer Survival Center ( Site 0125) | Knoxville | Tennessee | 37916 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 117 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07227402, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 2, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07227402 live on ClinicalTrials.gov.